Roger Knaggs

Associate professor in clinical pharmacy practice

Role in PharmNovo: Scientific advisor.

University: University of Nottingham.

Resumé: Roger has undergraduate degrees in Science (Pharmacy) and Biomedical sciences and a PhD from the University of Nottingham. He was an Advanced Pharmacy Practitioner at Nottingham University Hospital prior to his current academic appointment. He is a Fellow of the Faculty of Pain Medicine, Chair of the UK Clinical Pharmacy Association pain management group, a member of the British Pain Society Council and the UK Advisory Council on the Misuse of Drugs. He is the media spokesperson on pain management for the Royal Pharmaceutical Society and British Pain Society in both online and traditional media, including newspapers, magazines, radio and television. Roger is a specialist in the management of chronic pain with particular expertise in the clinical pharmacology of opioids.

Member of:

Clinical

Latest news

View all

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Meet Bengt von Mentzer, founder and Chief scientific advisor

March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.

January 30, 2024

NIDA funds studies

The US National Institute of Drug Abuse (NIDA) has funded a project investigating the drug candidate PN6047, a novel and highly selective Delta Opioid Receptor Agonist (DORA), represents a unique approach to addressing this medical challenge.

Meet Olof Breuer, MD, Clinical pharmacology lead

January 30, 2024

Meet Olof Breuer, MD, Clinical pharmacology lead

Olof Breuer's presence at PharmNovo exemplifies the company's commitment to pioneering advancements in pain relief. His visionary approach, honed through years of experience, positions him as a driving force in the quest for novel concepts in neuropathic pain relief.